[Breast implants and cancer: Anaplastic large cell lymphoma in breast implants]

This article aims to provide recommendations on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), caused by textured breast implants. These recommendations are based on both updated data from the literature and the experience gained in the management and treatment of patients by the French-speaking Adult Lymphoma Study Group, Lymphoma Study Association (LYSA), regarding BIA-ALCL. Studies indexed in PubMed, focusing on breast surgery and breast implant-associated lymphoma, published between 2006 and 2024, were included. The most relevant articles were analyzed to synthesize recommendations and determine the incidence, clinical presentation, risk factors, various therapeutic approaches, and follow-up strategies. Surgeons who implant breast prostheses must be aware of the specific risks associated with these medical devices. Short-term risks must be considered just as carefully as long-term risks. Technical modifications made by manufacturers to medical devices may introduce unexpected risks. Beyond the usual safety and regulatory procedures for introducing a medical device to the market, appropriate patient monitoring and the reporting of adverse events are essential prerequisites for causality investigations and potential corrective measures.